Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Pacira BioSciences Third Quarter Earnings Conference Call.
Pacira Biosciences Inc. (PCRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Impax Asset Management Ian Simm | 750,027 | $19,410,699 | +25% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.25 | 1,512 | $20,034.00 | 10,142 | 2024-08-16 | Filing | |
| $12.81 | 1,000 | $12,810.00 | 17,552 | 2024-08-16 | Filing | |
| $12.90 | 2,000 | $25,800.00 | 7,230 | 2024-08-14 | Filing | |
| $12.10 | 8,264 | $99,994.40 | 107,784 | 2024-08-12 | Filing | |
| $12.01 | 3,400 | $40,834.00 | 8,630 | 2024-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.24 | 1,416 | $34,323.84 | 59,064 | 2026-01-05 | Filing | |
| $25.14 | 9,104 | $228,874.56 | 56,250 | 2025-12-10 | Filing | |
| $25.03 | 15,896 | $397,876.88 | 56,250 | 2025-12-09 | Filing | |
| $24.09 | 3,960 | $95,396.40 | 178,367 | 2025-11-17 | Filing | |
| $22.09 | 12,060 | $266,405.40 | 56,250 | 2025-11-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,812,955 | $124,559,276 | 0% | |
| 2. | 558,651 | $14,457,888 | 0% | |
| 3. | 435,143 | $11,261,501 | 0.02% | |
| 4. | 9,000,000 | $9,073,072 | 1.03% | |
| 5. | 6,500,000 | $6,566,625 | 0.02% |
News See All
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Pacira Biosciences Q2 2025 Earnings Conference Call.
Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement
Pacira BioSciences Inc. (NASDAQ:PCRX) is one of the most undervalued small-cap stocks to buy according to analysts.
11 Most Undervalued Small-Cap Stocks to Buy According to Analysts
On July 2, Joe Amato, President and Chief Investment Officer at Neuberger Berman, joined 'Squawk Box' on CNBC to discuss the latest market trends.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the First Quarter 2025 Pacira BioSciences Earnings Conference Call. At this time, all participants are in listen-only mode.
10 Best Pharma Stocks to Buy for Long Term Growth
With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Pacira BioSciences Fourth Quarter 2024 Conference Call. [Operator Instructions].
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Third Quarter 2024 Pacira Biosciences Inc. Earnings Conference Call. At this time, all participants are listen only mode.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2024 Earnings Call Transcript
Operator: Good day. And thank you for standing by. Welcome to the Q2 2024 Pacira BioSciences Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Hedge Fund Resource Center Billionaire Hedge Funds
